MARKET WIRE NEWS

LifeStance Health Group Announces Launch of Secondary Public Offering

MWN-AI** Summary

LifeStance Health Group, Inc. (Nasdaq: LFST), a leading provider of virtual and in-person outpatient mental health care in the United States, announced on February 25, 2026, the launch of a secondary public offering of 25 million shares of its common stock, as disclosed in a filing with the Securities and Exchange Commission (SEC). The shares will be offered by certain stockholders, referred to as the Selling Stockholders, who will receive all proceeds from the sale. Importantly, LifeStance will not be selling any shares and will not benefit from the proceeds of this offering.

In conjunction with the secondary offering, LifeStance has authorized a repurchase of 7 million shares from the underwriter, priced equivalently to the offering price for the Selling Stockholders. The repurchase is contingent on the completion of the secondary offering and other customary conditions, but the offering itself is not dependent on this repurchase.

J.P. Morgan is acting as the underwriter for the offering. Investors are encouraged to read the prospectus and related documents for detailed information regarding the offering and LifeStance’s business, available on the SEC’s website.

Founded in 2017, LifeStance employs over 8,000 mental health professionals and operates more than 550 centers across 33 states, focusing on improved access to mental healthcare. The company’s mission centers on helping individuals lead healthier, fulfilling lives through trusted and personalized mental health services.

As with all forward-looking statements contained in the announcement, potential investors are cautioned to recognize the risks and uncertainties that may affect LifeStance’s anticipated results and performance. Cautionary statements highlight challenges related to reimbursement rates, competitive dynamics, growth management, regulatory compliance, and technological integrity that could impact the company’s operations and financial condition.

MWN-AI** Analysis

LifeStance Health Group, Inc. (Nasdaq: LFST) has recently announced its intention to launch a secondary public offering involving 25 million shares, primarily for the benefit of certain stockholders. This move could have significant implications for potential investors and market observers.

The company is not directly raising capital from the offering, which is crucial to note. Instead, the proceeds will benefit selling stockholders. This can indicate a liquidity event allowing these stakeholders to realize gains potentially amassed over time. Investors may interpret this shift in stock ownership as a reflection of confidence in the company's trajectory or a necessary cash-out by insiders.

Simultaneously, LifeStance plans to repurchase 7 million shares from the underwriter, an action often seen as a positive signal. Share repurchases can reduce the total number of shares outstanding, potentially increasing earnings per share and indicating the company’s belief in its value. However, it's essential to assess whether this buyback ultimately supports stock prices sustainably or simply serves as a short-term boost.

Investors should remain cautious. LifeStance operates in a highly regulated and competitive healthcare environment, raising questions about future growth potential and operational risks. The mention of uncertainties, including reimbursement rate pressures and cybersecurity threats, is a prudent reminder that, despite the promising landscape for mental health services, challenges lie ahead.

As a financial analyst, I advise staying updated on the performance of LifeStance shares post-offering and monitoring any subsequent financial reports. Additionally, review the company's key performance indicators, focusing on revenue growth, and clinician recruitment efforts. Given the nuanced implications of the offering, a prudent approach would be to balance investment in LifeStance with an awareness of the broader market conditions affecting healthcare stocks.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 25,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has authorized the concurrent purchase from the underwriter of 7,000,000 shares of Common Stock (the “Repurchase”), subject to the completion of the offering. The price per share for the shares to be repurchased by the Company will be the same as the price per share payable by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The Repurchase will be subject to completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering will be made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ approximately 8,040 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company.
Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.


Investor Relations ContactMonica ProkockiVP of Finance & Investor Relations602-767-2100investor.relations@lifestance.com

FAQ**

What impact do you anticipate the offering of 25 million shares by Selling Stockholders will have on LifeStance Health Group Inc. (LFST) stock price and investor sentiment moving forward?

The offering of 25 million shares by Selling Stockholders is likely to dilute LifeStance Health Group Inc. (LFST)'s stock price and could negatively impact investor sentiment, as it may signal concerns about the company's valuation or fundraising needs.

How does the concurrent repurchase of 7 million shares by LifeStance Health Group Inc. (LFST) reflect the Company’s confidence in its future growth and potential profitability?

The concurrent repurchase of 7 million shares by LifeStance Health Group Inc. signals management's strong belief in the company's growth prospects and future profitability, as they invest in its own equity to enhance shareholder value and demonstrate commitment to sustainable success.

Given the risks outlined, how does LifeStance Health Group Inc. (LFST) plan to mitigate challenges related to clinician recruitment and maintaining competitive advantages in the mental health industry?

LifeStance Health Group Inc. (LFST) plans to mitigate clinician recruitment challenges and maintain competitive advantages by investing in attractive compensation packages, enhancing workplace culture, providing robust training programs, and leveraging technology for operational efficiency.

In light of potential regulatory changes, what strategies is LifeStance Health Group Inc. (LFST) implementing to ensure compliance and safeguard its operational integrity?

LifeStance Health Group Inc. (LFST) is enhancing its compliance framework and risk management practices, investing in technology solutions for real-time monitoring, and fostering a culture of accountability to adapt to potential regulatory changes while safeguarding operational integrity.

**MWN-AI FAQ is based on asking OpenAI questions about LifeStance Health Group Inc. (NASDAQ: LFST).

LifeStance Health Group Inc.

NASDAQ: LFST

LFST Trading

-2.62% G/L:

$6.31 Last:

1,365,811 Volume:

$6.36 Open:

mwn-link-x Ad 300

LFST Latest News

LFST Stock Data

$2,699,661,950
138,095,100
0.52%
69
N/A
Healthcare Providers & Services
Healthcare
US
Scottsdale

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App